vs
Amneal Pharmaceuticals, Inc.（AMRX）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是ROYAL GOLD INC的1.9倍（$722.5M vs $375.3M），ROYAL GOLD INC净利率更高（24.9% vs 10.8%，领先14.1%），ROYAL GOLD INC同比增速更快（85.3% vs 3.9%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs 1.5%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
AMRX vs RGLD — 直观对比
营收规模更大
AMRX
是对方的1.9倍
$375.3M
营收增速更快
RGLD
高出81.4%
3.9%
净利率更高
RGLD
高出14.1%
10.8%
两年增速更快
RGLD
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $375.3M |
| 净利润 | $78.0M | $93.6M |
| 毛利率 | 44.3% | 64.6% |
| 营业利润率 | — | 56.2% |
| 净利率 | 10.8% | 24.9% |
| 营收同比 | 3.9% | 85.3% |
| 净利润同比 | 217.0% | -12.8% |
| 每股收益（稀释后） | $0.19 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRGLD
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $375.3M | ||
| Q3 25 | $784.5M | $252.1M | ||
| Q2 25 | $724.5M | $209.6M | ||
| Q1 25 | $695.4M | $193.4M | ||
| Q4 24 | $730.5M | $202.6M | ||
| Q3 24 | $702.5M | $193.8M | ||
| Q2 24 | $701.8M | $174.1M |
净利润AMRXRGLD
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $93.6M | ||
| Q3 25 | $2.4M | $126.8M | ||
| Q2 25 | $22.4M | $132.3M | ||
| Q1 25 | $12.2M | $113.5M | ||
| Q4 24 | $-31.1M | $107.4M | ||
| Q3 24 | $-156.0K | $96.2M | ||
| Q2 24 | $6.0M | $81.2M |
毛利率AMRXRGLD
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 64.6% | ||
| Q3 25 | 34.9% | 73.6% | ||
| Q2 25 | 39.5% | 72.6% | ||
| Q1 25 | 36.8% | 69.4% | ||
| Q4 24 | 36.0% | 70.3% | ||
| Q3 24 | 38.4% | 66.6% | ||
| Q2 24 | 35.6% | 64.7% |
营业利润率AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 56.2% | ||
| Q3 25 | 9.0% | 64.4% | ||
| Q2 25 | 15.4% | 67.7% | ||
| Q1 25 | 14.4% | 63.6% | ||
| Q4 24 | 10.4% | 65.9% | ||
| Q3 24 | 12.6% | 61.3% | ||
| Q2 24 | 13.6% | 58.6% |
净利率AMRXRGLD
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 24.9% | ||
| Q3 25 | 0.3% | 50.3% | ||
| Q2 25 | 3.1% | 63.1% | ||
| Q1 25 | 1.8% | 58.7% | ||
| Q4 24 | -4.3% | 53.0% | ||
| Q3 24 | -0.0% | 49.7% | ||
| Q2 24 | 0.9% | 46.6% |
每股收益（稀释后）AMRXRGLD
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $1.04 | ||
| Q3 25 | $0.01 | $1.92 | ||
| Q2 25 | $0.07 | $2.01 | ||
| Q1 25 | $0.04 | $1.72 | ||
| Q4 24 | $-0.10 | $1.63 | ||
| Q3 24 | $0.00 | $1.46 | ||
| Q2 24 | $0.02 | $1.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $233.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.2B |
| 总资产 | — | $9.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $233.7M | ||
| Q3 25 | $201.2M | $172.8M | ||
| Q2 25 | $71.5M | $248.2M | ||
| Q1 25 | $59.2M | $240.8M | ||
| Q4 24 | $110.6M | $195.5M | ||
| Q3 24 | $74.0M | $127.9M | ||
| Q2 24 | $43.8M | $74.2M |
总债务AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | $0 | ||
| Q2 24 | $2.4B | $50.0M |
股东权益AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $7.2B | ||
| Q3 25 | $-109.5M | $3.4B | ||
| Q2 25 | $-112.1M | $3.3B | ||
| Q1 25 | $-131.7M | $3.2B | ||
| Q4 24 | $-109.3M | $3.1B | ||
| Q3 24 | $-93.4M | $3.0B | ||
| Q2 24 | $-57.5M | $3.0B |
总资产AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $9.5B | ||
| Q3 25 | $3.6B | $4.5B | ||
| Q2 25 | $3.4B | $3.6B | ||
| Q1 25 | $3.4B | $3.5B | ||
| Q4 24 | $3.5B | $3.4B | ||
| Q3 24 | $3.5B | $3.3B | ||
| Q2 24 | $3.5B | $3.3B |
负债/权益比AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $241.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 2.58× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $241.7M | ||
| Q3 25 | $118.5M | $174.0M | ||
| Q2 25 | $83.8M | $152.8M | ||
| Q1 25 | $7.4M | $136.4M | ||
| Q4 24 | $118.1M | $141.1M | ||
| Q3 24 | $141.8M | $136.7M | ||
| Q2 24 | $39.7M | $113.5M |
自由现金流AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — |
自由现金流率AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — |
资本支出强度AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — |
现金转化率AMRXRGLD
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 2.58× | ||
| Q3 25 | 50.00× | 1.37× | ||
| Q2 25 | 3.74× | 1.15× | ||
| Q1 25 | 0.61× | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | 6.62× | 1.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
